• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

May 14, 2018
Company Drug/Device Medical Condition Status
Nektar Therapeutics NKTR-358 systemic lupus erythematosus (SLE) Phase Ib trial initiated evaluating 50 subjects
Bonti, Inc. EB-001T elective abdominoplasty surgery Phase II trial initiated
Amneal IPX203 advanced Parkinson’s disease Phase III trial initiated to enroll 500 subjects
Prisyna, the oral care division of Synedgen Moisyn product line xerostomia 510(k) clearance granted by the FDA
C4 Imaging LLC HDR MRI Marker use prior to high dose rate (HDR) brachytherapy to accurately locate the position of the applicators that guide the placement of radioactive sources for the treatment of multiple cancers 510(k) clearance granted by the FDA
Palladio Biosciences. Inc. lixivaptan capsules autosomal dominant polycystic kidney disease (ADPKD) IND clearance granted by the FDA
Portola Pharmaceuticals Andexxa antidote for blood thinners rivaroxaban and apixaban Approval granted by the FDA
Janssen Pharmaceutical Companies of Johnson & Johnson DARZALEX (daratumumab) in combination with VELCADE (bortezomib), a proteasome inhibitor (PI); melphalan, an alkylating agent; and prednisone - VMP newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT) Approval granted by the FDA
PaxVax, Inc. Chikungunya vaccine prevention of the chikungunya virus Fast Track Designation granted by the FDA
Debiopharm International SA Debio 1347 (FGFR 1-3 Inhibitor) unresectable or metastatic tumors with a specific FGFR gene alteration Fast Track Designation granted by the FDA
Genentech Tecentriq triple combination with Avastain (bevacizumab), paclitaxel and carboplatin (chemotherapy) first-line treatement of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) Priority Review granted by the FDA

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing